Acquisition Expansion Strategic acquisition of Pharmafluidics in November 2021 expands TREK Diagnostics Systems into muPAC microchip based chromatography, enabling cross selling of microfluidic columns and end to end chromatography solutions to pharma, biotech, CROs and academic labs.

Public Health Growth In December 2021 TREK Diagnostics Systems announced expansion of the K 12 ReadyCheckGo COVID 19 testing solution in Texas, signaling ability to scale diagnostics programs in education and public sector channels. This creates sales opportunities with school districts, public health agencies, and state procurement programs for turnkey testing, reagents, installation, and service.

Instrument Leadership TREK Diagnostics Systems' portfolio includes high performance Vanquish Core HPLC systems, highlighting capability in robust analytical instrumentation. Combined with the Pharmafluidics acquisition, the company can offer integrated chromatography platforms and muPAC microfluidic consumables to pharma, biotech, CROs and academic labs.

Channel Growth As a mid sized US manufacturer with revenue in the 1M to 10M range, TREK Diagnostics Systems has opportunity to expand through regional distributors and strategic partnerships, enabling faster reach to research labs, contract labs, and healthcare and education customers with flexible pricing and service options.

Market Trends Alignment Current activity shows TREK Diagnostics Systems aligning with rising demand for advanced chromatography and microfluidic solutions in life sciences, pharma and diagnostics. This creates cross sell opportunities for instruments, consumables such as microfluidic columns, and ongoing service contracts as labs invest in scalable analytics and testing capabilities.